Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490790 | 0.88 | KIF11 (0.50) | KIF11TAAR1SLC6A1LOXL2KCNN4 | |
| SCHEMBL2490391 | 0.79 | KIF11 (0.64) | KIF11TAAR1SMN1; SMN2SLC6A11AGXT | |
| SCHEMBL2493499 | 0.79 | SLC6A1 (0.43) | KIF11SLC6A1KCNN4ALDH1A1SMN1; SMN2 | |
| SCHEMBL2492363 | 0.78 | KIF11 (1.00) | KIF11TAAR1SLC6A1KCNN4ALDH1A1 | |
| SCHEMBL2489501 | 0.76 | RORC (0.42) | KIF11SLC6A1KCNN4ALDH1A1SMN1; SMN2 | |
| SCHEMBL2490800 | 0.76 | KIF11 (0.60) | KIF11TAAR1SMN1; SMN2MAOBSLC6A11 | |
| SCHEMBL12199498 | 0.73 | KIF11 (0.79) | KIF11SMN1; SMN2 | |
| SCHEMBL2492907 | 0.72 | KIF11 (0.70) | KIF11TAAR1KCNN4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3617308 | 0.71 | KIF11 (0.73) | KIF11SLC6A1SMN1; SMN2SLC6A11 | |
| SCHEMBL2490823 | 0.71 | KIF11 (0.73) | KIF11SLC6A1SMN1; SMN2SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | KIF11 4556/4885TAAR1 225/4885SLC6A1 644/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | KIF11 4605/4885TAAR1 194/4885SLC6A1 710/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | KIF11 4611/4885TAAR1 225/4885SLC6A1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.